# Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide.

> **NCT07391267** · NA · NOT_YET_RECRUITING · sponsor: **Institute of Liver and Biliary Sciences, India** · enrollment: 90 (estimated)

## Conditions studied

- Chronic Kidney Diseases
- MAFLD

## Interventions

- **DRUG:** Semaglutide Oral Tablet
- **OTHER:** Placebo
- **OTHER:** Standard medical treatment

## Key facts

- **NCT ID:** NCT07391267
- **Lead sponsor:** Institute of Liver and Biliary Sciences, India
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02-01
- **Primary completion:** 2028-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2026-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07391267

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07391267, "Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide.". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT07391267. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*